Researchers have developed a more efficient and cost-saving method
to make cladribine, a drug used for the treatment of certain types
of leukaemia and potentially efficient against multiple sclerosis
Researchers believe that a genetic discovery involving a cellular
signal that aggravates the symptoms of MS may be a viable target in
new therapeutic approaches, which could alleviate the burden of
this debilitating neurological disease.
A new laboratory method, which looks for a spinal fluid protein,
may identify people with the earliest stages of multiple sclerosis
(MS), greatly increasing the effectiveness of drug therapies to
treat the 10,000 Americans, who are...
Serono has announced a mixed third quarter 2005 with product sales
and total revenues weaker than predicted. Its net income beat
market consensus but the company was hit by an $18.3 million (€15.2
million) one-off charge related to...
The interest in Syntonix' SynFusion and Transceptor technologies
intensified as Boehringer Ingelheim became the second
pharmaceutical company to use this technology to optimise its
therapeutic peptides for inhalation.
German pharmaceutical firm, Schering took the opportunity, during
the company’s annual financial meeting, to provide an update on its
drug development pipeline, which concentrates on the disease areas
of hormonal therapies, cancer...
Teva Pharmaceutical Industries' active pharmaceutical ingredients
(API) business is on track to become a $1 billion enterprise this
year, although growth in the first quarter of this year was almost
entirely from in-house sales,...
Researchers have identified a common gene variant that could be a
risk factor behind a number of common diseases such as
cardiovascular disease, rheumatism and Multiple Sclerosis (MS), of
which up to a quarter of the population could...
Serono and Syntonix Pharmaceuticals announced today that they have
entered into an agreement that allows Serono the exclusive rights
to use Syntonix' Transceptor and Synfusion technologies for the
development and commercialisation...
Researchers at the Serono Genetics Institute have announced the
identification of 80 genes involved in the inflammatory and
neuro-degenerative pathways of multiple sclerosis (MS) forming a
library of potential targets for future treatments...
The first in a completely new class of drug for multiple sclerosis
has been approved in the US, opening up a new avenue of treatment
for sufferers of the debilitating diseases and potential
blockbuster revenues for developers Elan...